Abstract
Objective To compare oncologic outcomes of South Asian (SA) patients treated at a regional cancer centre in Canada, for oral squamous cell carcinoma (OSCC), to the general population.
Methods Adult patients who underwent primary surgical resection of OSCC +/- adjuvant treatment between 2009 and 2022 (N=697) were included. SA patients were identified using a validated method and compared to non-SA patients. Baseline characteristics, including betel nut consumption, were compared, and disease-specific survival (DSS) and recurrence-free survival (RFS) were evaluated using Kaplan-Meier methods, with median follow-up time of 36.4 months [SD 31.02]. Cox proportional hazard regression models adjusted for potential confounders. A p-value < 0.05 was considered statistically significant.
Results SA patients (9% of cohort, n = 64) were significantly younger and had lower rates of smoking and alcohol consumption compared to non-SA patients. There were no differences in tumor characteristics or the use of adjuvant radiation. SA patients had a two-fold higher risk of recurrence and significantly worse disease-specific survival, even after adjusting for stage and high-risk features [RFS: HR 2.01(1.28 - 3.14), DSS: HR 1.79(1.12 - 2.88)]. The consumption of betel nut was not associated with outcomes.
Conclusion To our knowledge, this study is the first to compare the oncological outcomes of SA patients with OSCC to non-SA patients. SA patients had significantly worse outcomes, even after controlling for known predictors of recurrence and disease-specific survival. These findings can inform personalized treatment decisions and influence public health policies when managing patients with different ethnic backgrounds.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
University of Calgary Conjoint Health Research Ethics Board
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
